⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Spyre Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Spyre Therapeutics
↗Waltham, USA
Spyre Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody therapeutics for inflammatory bowel disease (IBD) and other immune-mediated diseases. The company leverages advanced antibody engineering, rational therapeutic combinations, and precision medicine to create long-acting therapies with extended half-lives.
Spyre's pipeline targets critical pathways including α4β7, TL1A, and IL-23. The company aims to redefine the standard of care by improving response durability, safety, and patient adherence through innovative scientific research and clinical development strategies.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2013
Ownership:public
Status:operating
FUNDING
Stage:Public
STOCK
Exchange:NASDAQ
Ticker:SYRE
Market Cap:$6.52B
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2
Modalities:Monoclonal antibodies, Long-acting antibodies
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Cameron Turtle - CEO
Scott Burrows - CFO
Sheldon Sloan - CMO
LINKS
Website:spyre.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Spyre Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.